Objective Based on the neuroprotective effects of granulocyte colony-stimulating factor (G-CSF) on experimental spinal cord injury, we initiated a clinical trial that evaluated the safety and efficacy of neuroprotective therapy using G-CSF for patients with worsening symptoms of compression myelopathy. Methods We obtained informed consent from 15 patients, in whom the Japanese Orthopaedic Association (JOA) score for cervical myelopathy decreased two points or more during a recent 1-month period. G-CSF (5 or 10 lg/kg/day) was intravenously administered for five consecutive days. We evaluated motor and sensory functions of the patients and the presence of adverse events related to G-CSF therapy.
Introduction
Chronic compression of the spinal cord by osteophytes and ossification of the posterior longitudinal ligament (OPLL) causes compression myelopathy [1, 6] . Such myelopathy usually progresses with a slow, stepwise decline in function. In some patients, however, motor paresis and paresthesia rapidly progress with mild or no trauma. According to a previous study, the severity of compression myelopathy rapidly worsened in almost 5% of patients [19] . Rapidly worsening compressive myelopathy results in severe neurological deficits with poor functional recovery because of limited axonal regeneration [1, 3, 6, 24] . To date, early surgical treatment has been the only effective therapy [17, 25] .
Granulocyte colony-stimulating factor (G-CSF) is a 19.6 kDa glycoprotein. This cytokine promotes survival, proliferation, and differentiation of cells in the neutrophil lineage [13, 16] . Furthermore, G-CSF can mobilize both immature and mature bone marrow cells into the peripheral blood. As a result, it is used clinically for patients with leukocytopenia and for donors of peripheral blood-derived hematopoietic stem cells for transplantation. Several recent reports have indicated that G-CSF also has nonhematopoietic functions and can potentially be used for the treatment of neuronal injury, including stroke and neurodegenerative diseases [4, 7, 9, 18, 20] . We previously demonstrated that G-CSF promoted the restoration of damaged spinal cord tissue and the recovery of neural function in experimental spinal cord injury in both mice and rats [8, 14] . In addition, we showed that G-CSF promoted the migration of bone marrow-derived cells into the damaged spinal cord, suppressed apoptosis of neuronal cells and oligodendrocytes, protected myelin, decreased inflammation, and promoted angiogenesis [8, 14] . Based on these results, we have suggested that G-CSF is a candidate for neuroprotective therapy for worsening symptoms of compression myelopathy.
Recently, we began a phase I and IIa clinical trial for the purpose of evaluating the safety and efficacy of neuroprotective therapy using G-CSF for patients with worsening symptoms of compression myelopathy. In the present study, we evaluated the results of this trial.
Methods
This clinical trial was performed with the approval of the Institutional Review Board of our university. We recruited patients 20-75 years of age, in whom the Japanese Orthopaedic Association (JOA) score for cervical myelopathy decreased two points or more during a recent 1-month period. We excluded patients in the following categories: (1) those with intracranial pathologies (e.g., tumors, infection, or ischemia); (2) those having a history of major bleeding requiring blood transfusion or a history of leukopenia, thrombocytopenia, or hepatic or renal dysfunction, severe heart failure, or splenomegaly; (3) those with evidence of malignant disease within the past 5 years. We also excluded patients who were pregnant or nursing. Eligible patients gave informed consent for participation in the trial.
In the first stage of this trial, G-CSF (5 lg/kg/day) was intravenously administered for five consecutive days (the 5-lg group). We conducted an open-label study, and a control group was not used. We evaluated common criteria for adverse event reporting, version 3.0. We also evaluated the patients' severity of myelopathy, using JOA scores (cervical myelopathy scores range from 0 to 17, thoracic myelopathy scores range from 0 to 11) [10] . We then evaluated their motor and sensory functions by calculating scores of muscle power, touch sensation, and pain sensation according to the American Spinal Injury Association (ASIA) score (motor scores range from 0 to 100, light touch and pin prick scores range from 0 to 112) [11] . In the present study, two orthopedic spine surgeons specializing in cervical and thoracic spine surgery evaluated patients' neurological status independently every month until 6 months after G-CSF administration, and calculated the mean data. In addition, we analyzed hematological data from the treated patients. During the first stage (the 5-lg group), we did not restrict the time of surgery of patients and performed surgical treatment according to the patients' directives.
At the second stage, G-CSF (10 lg/kg/day) was similarly administered for five consecutive days (the 10-lg group). We evaluated adverse events, JOA score, scores of muscle power, touch sensation and pain sensation, and hematological data, as done with the 5-lg group. A major difference of the study design between the 5-lg group and the 10-lg group was a restriction of the time of surgery after G-CSF administration. In the 10-lg group, to evaluate neurological improvement resulting from neuroprotective therapy with G-CSF, we planned to follow patients without surgical treatment for 1 month after G-CSF administration. When patients were given informed consent documents, we explained our plans regarding the time of surgery, and we administered G-CSF only to those patients who agreed with the protocol. One month after G-CSF administration, we performed surgical treatment according to the patients' wishes. But when myelopathy progressed and patients wanted to initiate surgery, we abandoned the original schedule and performed surgery according to the patients' requests regardless of the timing relative to G-CSF administration.
Statistical analysis was performed using a Mann-Whitney U test. A p value \0.05 was considered statistically significant. Results are presented as mean values ± standard deviation of the mean.
Results

The 5-lg group
Between June 2008 and May 2009, a total of five patients were enrolled in the first stage of this trial, and all the patients had cervical and/or thoracic myelopathy due to ossification of the spinal ligament, such as OPLL and ossification of the ligamentum flavum (OLF) ( Table 1) . In all five of the patients, the JOA score decreased two points or more over a recent 1-month period (Table 2) . Neurological improvements in both motor and sensory functions were observed in all five patients by the seventh day following the start of G-CSF administration, though the degree of the improvement differed depending on the patient (Table 4 ). The five patients underwent surgical treatment after G-CSF administration; one patient underwent posterior decompression and four patients posterior decompression with instrumented fusion. The time between the first day of G-CSF administration and surgery ranged from 9 to 115 days. One day after the start of G-CSF therapy, the white blood cell (WBC) count increased to more than 15,200 cells/mm 3 (Table 5 ). It remained elevated (from 15,200 to 43,200) during the administration, and returned to preadministration levels within 3 days of the final G-CSF treatment. G-CSF selectively mobilized cells of the neutrophil lineage, while neither monocytes nor lymphocytes were affected (Table 5 ). There was no change in inflammation during G-CSF administration, as indicated by C-reactive protein levels, except for an instance of surgical site infection (Table 5) . One patient (case 4) developed a surgical site infection 14 days after G-CSF administration (5 days after surgery). The infection was relieved by debridement of the infection site and administration of antibiotics. No relation was found between the infection and the G-CSF administration. No other adverse event occurred during or after the administration.
The 10-lg group Between July 2009 and February 2010, a total of ten patients were enrolled in the second stage of this trial: six patients had cervical and thoracic myelopathy because of ossification of the spinal ligament, such as OPLL and OLF, and four patients had cervical spondylotic myelopathy (CSM) ( Table 1) . In all ten of the patients, the JOA score had decreased two points or more over a recent 1-month period (Table 3) . One month after administration, the mean M male, T thoracic, OLF ossification of ligamentum flavum, PD posterior decompression, OPLL ossification of the posterior longitudinal ligament, PDF posterior decompression with instrumented fusion, C cervical, NS no surgery Mean ± SD 54.0 ± 26.4
Recovery rate = (postoperative score -preoperative score/full score -preoperative score) 9 100 (%)
JOA score Japanese Orthopaedic Association score (cervical myelopathy: 0-17 points, thoracic myelopathy: 0-11 points)
JOA recovery rate was 49.9 ± 15.1% (Table 3) , and the muscle power score was significantly improved compared with that before G-CSF administration (Table 4) . Nine patients underwent surgical treatment at 1 month or later after G-CSF administration. Six months after administration, the mean JOA recovery rate was 59.1 ± 16.3% (Table 2) , and scores of muscle power, touch sensation, and pain sensation were significantly improved compared with those before G-CSF administration (Table 4) . One day after the start of G-CSF therapy, the WBC count increased to more than 22,700 (Table 5 ). It remained elevated (up 12,500 to 50,000) during the administration, and returned to preadministration levels within 3 days of the final G-CSF treatment. G-CSF successfully mobilized cells of the neutrophil lineage, but neither monocytes nor lymphocytes were affected (Table 5 ). There was no significant change in inflammation during G-CSF administration, as indicated by C-reactive protein levels (Table 5) . No adverse event occurred during or after the administration.
Case presentation
Case 7
A 67-year-old man was admitted to our hospital with a complaint of progression of myelopathy. Over the preceding 2 weeks, a loss of muscle power in his upper and lower Recovery rate = (postoperative score -preoperative score/full score -preoperative score) 9 100 (%)
JOA score Japan Orthopaedic Association score (cervical myelopathy: 0-17 points, thoracic myelopathy: 0-11 points) Table 4 Scores of muscle power, touch sensation, and pain sensation before and after G-CSF administration extremities had rapidly progressed, and gait disturbance developed. Previously, he had undergone surgical treatment for cervical myelopathy because of OPLL: C3-C7 laminoplasty at 64 years of age. After that operation, he could run and slight numbness was present at his finger; his JOA scale score was 16.5 points at 1 month before administration. On admission, he showed severe loss of sensation below the C6-T1 dermatome level, and muscle strength of his upper extremities decreased to 2-4/5 and lower extremities decreased to 4/5 in manual muscle testing. He could not walk without a cane for assistance. Deep tendon reflexes were hyperactive in bilateral triceps tendons and lower extremities, and Babinski's sign was positive bilaterally. His bladder function was normal, and his JOA score was 11.5 points. Examination with computed tomography (CT) and magnetic resonance (MR) imaging showed anterior compression of the spinal cord by segmental type OPLL at C3-C7 (Fig. 1) . Especially at C5-C6, an ossified mass caused severe anterior compression to the spinal cord.
He underwent G-CSF administration (10 lg/kg/day) for 5 days. On the fourth day of G-CSF administration, he felt improved muscle strength in both arms and legs. The G-CSF-induced improvement of motor and sensory functions reached a peak level 2 weeks after G-CSF administration; he could walk without a cane, and no deterioration occurred during the following 6 months. He felt no difficulties in daily life, and he returned to his work 3 months after G-CSF administration.
Discussion
In June 2008, we started a phase I and IIa clinical trial that evaluated the safety and efficacy of neuroprotective therapy using G-CSF for patients with worsening symptoms of compression myelopathy. During the first stage of this trial, G-CSF (5 lg/kg/day) was intravenously administered for five consecutive days. The results indicated that neurological improvements in both motor and sensory functions were obtained in all patients, although the degree of improvement differed depending on the patient. No serious adverse events occurred during or after the administration. Previous studies of G-CSF therapy for acute myocardial infarction, acute cerebral infarction, and amyotrophic lateral sclerosis [2, 5, 12, 15, 21-23, 26, 27] have used a dose of 10 lg/kg/day G-CSF for five consecutive days (Table 6) . Therefore, we administered 10 lg G-CSF/kg/day intravenously for five consecutive days for the second stage of this trial. No adverse events occurred, and all patients have shown neurological improvements. This suggests that G-CSF therapy at a dose of 10 lg/kg/day for 5 days is safe for patients with worsening symptoms of compression myelopathy. Table 5 Blood data before and after G-CSF administration In the present study, the increase of WBC counts after G-CSF administration was lower than that in other clinical studies using G-CSF [2, 5, 12, 15, 21-23, 26, 27] . One of the reasons for this seems to be that we performed G-CSF therapy for a chronic disease, whereas other studies performed G-CSF therapy for the acute phase of disease. In addition, we suggest that the route of G-CSF administration could contribute to the lower WBC increases in the present study. G-CSF was intravenously administered in our study, while it was subcutaneously administered in other studies [2, 5, 12, 15, 21-23, 26, 27] .
In the ten patients enrolled in the second stage of this trial, G-CSF suppressed the progression of myelopathy. In addition, neurological improvements in both motor and sensory functions were obtained in all patients. The study design was open-label, and no control group was instituted. In spite of such limitations, the present results indicate that G-CSF had a neuroprotective effect on worsening symptoms of compression myelopathy.
In this trial, one patient (case 7) did not choose surgery because neurological recovery after the G-CSF administration was evident. In other cases, neurological improvement was also obtained though the degree of improvement differed among individual cases. This result indicated that other cases in addition to case 7 might have been able to avoid surgery. We suggest that by introducing G-CSF neuroprotective therapy, extremely conservative treatment may be possible for patients with worsening symptoms of compression myelopathy, and surgical treatment can be avoided in some patients. We had planned a third stage for this clinical trial with G-CSF administration of 15 lg/kg/day for 5 days. Based on the present results, however, we cancelled the third stage because G-CSF therapy at a dose of 10 lg/kg/day caused sufficient neurological improvement. In addition, G-CSF therapy at a dose of 10 lg/kg/day increased WBC counts to 50,000 cells/mm 3 in one patient. Thus, it is possible that G-CSF therapy at a dose of 15 lg/kg/day could cause side effects.
We intend to advance to a phase IIb clinical trial for accurate assessment of the efficacy of G-CSF therapy. Based on the present results, we will use G-CSF at a dose of 10 lg/kg/day for 5 days. The study design will be a multi-center prospective controlled clinical trial, and a control group without G-CSF administration will be incorporated. By undertaking this phase IIb clinical trial, we wish to establish the efficacy of the G-CSF neuroprotective therapy for patients with worsening symptoms of compression myelopathy. To date, there have been no reports of a drug that improves neurological status in patients with worsening symptoms of compression myelopathy. If the efficacy and safety of G-CSF treatment for worsening symptoms of compression myelopathy are established and clinical use of G-CSF neuroprotective therapy is approved, a novel and effective approach for the treatment of this disorder will be available.
